Dr Reddys Labs relaunches Zenatane-generic version of Accutane in US
Zenatane (lsotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg is being launched with an approved Risk Evaluation and Mitigation Strategy (REMS) Program. The product is a therapeutic equivalent generic version of Accutane.
New Delhi: Hyderabad-based Dr Reddy's Laboratories Ltd. (Dr Reddy’s) recently announced the relaunch of Zenatane (lsotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg a therapeutic equivalent generic version of Accutane, approved by the U.S. Food and Drug Administration (USFDA).
Accutane capsule is used to treat severe cystic acne (also known as nodular acne) that has not responded to other treatment.
Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr Reddy's offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated formulations. The major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. DRL operates in markets across the globe.
Also Read: Dr Reddys launches Tadalafil tablets for treating erectile dysfunction
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd